SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium.

Li, H; Terry, MB; Antoniou, AC; Phillips, K-A; Kast, K; Mooij, TM; Engel, C; Noguès, C; Stoppa-Lyonnet, D; Lasset, C; et al. Li, H; Terry, MB; Antoniou, AC; Phillips, K-A; Kast, K; Mooij, TM; Engel, C; Noguès, C; Stoppa-Lyonnet, D; Lasset, C; Berthet, P; Mari, V; Caron, O; Barrowdale, D; Frost, D; Brewer, C; Evans, DG; Izatt, L; Side, L; Walker, L; Tischkowitz, M; Rogers, MT; Porteous, ME; Snape, K; EMBRACE study; Meijers-Heijboer, HEJ; Gille, JJP; Blok, MJ; Hoogerbrugge, N; HEBON Investigators; Daly, MB; Andrulis, IL; Buys, SS; John, EM; McLachlan, S-A; Friedlander, M; kConFab Investigators; Tan, YY; Osorio, A; Caldes, T; Jakubowska, A; Simard, J; Singer, CF; Olah, E; Navratilova, M; Foretova, L; Gerdes, A-M; Roos-Blom, M-J; Arver, B; Olsson, H; Schmutzler, RK; Hopper, JL; Milne, RL; Easton, DF; Van Leeuwen, FE; Rookus, MA; Andrieu, N; Goldgar, DE; GENEPSO study (2020) Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. Cancer Epidemiol Biomarkers Prev, 29 (2). pp. 368-378. ISSN 1538-7755 https://doi.org/10.1158/1055-9965.EPI-19-0546
SGUL Authors: Snape, Katie Mairwen Greenwood

[img] PDF Accepted Version
Restricted to Repository staff only until 2 December 2020.
Available under License ["licenses_description_publisher" not defined].

Download (1MB)

Abstract

BACKGROUND: Tobacco smoking and alcohol consumption have been intensively studied in the general population to assess their effects on the risk of breast cancer, but very few studies have examined these effects in BRCA1 and BRCA2 mutation carriers. Given the high breast cancer risk for mutation carriers and the importance of BRCA1 and BRCA2 in DNA repair, better evidence on the associations of these lifestyle factors with breast cancer risk is essential. METHODS: Using a large international pooled cohort of BRCA1 and BRCA2 mutation carriers, we conducted retrospective (5,707 BRCA1 mutation carriers and 3,525 BRCA2 mutation carriers) and prospective (2,276 BRCA1 mutation carriers and 1,610 BRCA2 mutation carriers) analyses of alcohol and tobacco consumption using Cox proportional hazards models. RESULTS: For both BRCA1 and BRCA2 mutation carriers, none of the smoking-related variables was associated with breast cancer risk, except smoking for more than 5 years before a first full-term pregnancy (FFTP) when compared with parous women who never smoked. For BRCA1 mutation carriers, the HR from retrospective analysis (HRR) was 1.19 [95% confidence interval (CI), 1.02-1.39] and the HR from prospective analysis (HRP) was 1.36 (95% CI, 0.99-1.87). For BRCA2 mutation carriers, smoking for more than 5 years before an FFTP showed an association of a similar magnitude, but the confidence limits were wider (HRR = 1.25; 95% CI, 1.01-1.55 and HRP = 1.30; 95% CI, 0.83-2.01). For both carrier groups, alcohol consumption was not associated with breast cancer risk. CONCLUSIONS: The finding that smoking during the prereproductive years increases breast cancer risk for mutation carriers warrants further investigation. IMPACT: This is the largest prospective study of BRCA mutation carriers to assess these important risk factors.

Item Type: Article
Additional Information: © 2019 American Association for Cancer Research.
Keywords: EMBRACE study, HEBON Investigators, kConFab Investigators, GENEPSO study, 11 Medical and Health Sciences, Epidemiology
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Academic Structure > Molecular and Clinical Sciences Research Institute (MCS) > Cell Sciences (INCCCS)
Journal or Publication Title: Cancer Epidemiol Biomarkers Prev
ISSN: 1538-7755
Language: eng
Dates:
DateEvent
February 2020Published
2 December 2019Published Online
22 November 2019Accepted
Publisher License: Publisher's own licence
Projects:
Project IDFunderFunder ID
UM1CA164920National Cancer Institutehttp://dx.doi.org/10.13039/100000054
SAF2014-57680-RSpanish Ministry of Economy and CompetitivenessUNSPECIFIED
UNSPECIFIEDSpanish Research Network on Rare DiseasesUNSPECIFIED
CRN-87521Canadian Institutes of Health Researchhttp://dx.doi.org/10.13039/501100000024
PSR-SIIRI-701Ministry of Economic Development, Innovation and Export TradeUNSPECIFIED
UNSPECIFIEDGerman Cancer Research CenterUNSPECIFIED
C1287/A10118Cancer Research UKhttp://dx.doi.org/10.13039/501100000289
C1287/A11990Cancer Research UKhttp://dx.doi.org/10.13039/501100000289
IS-BRC-1215-20007National Institute for Health Researchhttp://dx.doi.org/10.13039/501100000272
C12292/A20861Cancer Research UKhttp://dx.doi.org/10.13039/501100000289
C12292/A11174Cancer Research UKhttp://dx.doi.org/10.13039/501100000289
110837German Cancer AidUNSPECIFIED
UNSPECIFIEDFondation de la FranceUNSPECIFIED
UNSPECIFIEDLigue Nationale Contre le CancerUNSPECIFIED
2014-008INCaUNSPECIFIED
RD12/0036/0006Instituto de Salud Carlos IIIhttp://dx.doi.org/10.13039/501100004587
15/0005Instituto de Salud Carlos IIIhttp://dx.doi.org/10.13039/501100004587
NKI1998-1854Dutch Cancer SocietyUNSPECIFIED
NKI2004-3088Dutch Cancer SocietyUNSPECIFIED
NKI2007-3756Dutch Cancer SocietyUNSPECIFIED
NWO 91109024Netherlands Organisation of Scientific ResearchUNSPECIFIED
110005Pink RibbonUNSPECIFIED
2014-187.WO76Pink RibbonUNSPECIFIED
NWO 184.021.007/CP46Biobanking and Biomolecular Resources Research InfrastructureUNSPECIFIED
JTC 2012 Cancer 12-054TranscanUNSPECIFIED
809195Cancer Australiahttp://dx.doi.org/10.13039/501100001111
1100868Cancer Australiahttp://dx.doi.org/10.13039/501100001111
IF 17Australian National Breast Cancer FoundationUNSPECIFIED
454508National Health and Medical Research Councilhttp://dx.doi.org/10.13039/501100000925
288704National Health and Medical Research Councilhttp://dx.doi.org/10.13039/501100000925
145684National Health and Medical Research Councilhttp://dx.doi.org/10.13039/501100000925
RO1CA159868National Institutes of Healthhttp://dx.doi.org/10.13039/100000002
00209805MH CZ-DROUNSPECIFIED
I-LO1413MEYS-NPSUNSPECIFIED
KTIA-OTKA CK-8074Hungarian ResearchUNSPECIFIED
NKFI OTKA K-112228Hungarian ResearchUNSPECIFIED
HU0115/NA/2008-3/ÖP-9Norwegian EEA Financial MechanismUNSPECIFIED
UNSPECIFIEDSwedish Cancer SocietyUNSPECIFIED
ERC-2011-294576European Research GrantUNSPECIFIED
PubMed ID: 31792088
Go to PubMed abstract
URI: http://openaccess.sgul.ac.uk/id/eprint/111612
Publisher's version: https://doi.org/10.1158/1055-9965.EPI-19-0546

Actions (login required)

Edit Item Edit Item